It's hard to see this as negative. It probably has low chance of a distant pay off but it is still a free spin of the wheel - possibly with better management!
The only possible negative is that it gives SPL an out when it comes to activity reporting and they try and claim credit for activities performed by another entity. I can't see it impacting any current work, the targets need to be agreed and I would hope that SPL wouldn't agree to anything they are already targeting.
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-19
-
- There are more pages in this discussion • 143 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
